Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.53 |
| ▸ | TBXAS1 | P24557 | 16/20 | 0.49 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9092744 | 0.82 | SIGMAR1 (0.53) | SIGMAR1TBXAS1TBXA2R | |
| SCHEMBL10585025 | 0.82 | SIGMAR1 (0.51) | SIGMAR1TBXAS1TBXA2R | |
| SCHEMBL28304994 | 0.81 | TBXAS1 (0.63) | SIGMAR1TBXAS1TBXA2R | |
| SCHEMBL1807584 | 0.80 | TBXAS1 (0.54) | SIGMAR1TBXAS1TBXA2R | |
| SCHEMBL14127624 | 0.79 | SIGMAR1 (0.53) | SIGMAR1TBXAS1TBXA2R | |
| SCHEMBL6897257 | 0.79 | SIGMAR1 (0.54) | SIGMAR1TBXAS1TBXA2R | |
| SCHEMBL8511316 | 0.79 | SIGMAR1 (0.53) | SIGMAR1TBXAS1TBXA2R | |
| SCHEMBL8216126 | 0.79 | SIGMAR1 (0.53) | SIGMAR1TBXAS1TBXA2R | |
| SCHEMBL29118795 | 0.79 | SIGMAR1 (0.49) | SIGMAR1TBXAS1TBXA2R | |
| SCHEMBL9882949 | 0.78 | SIGMAR1 (0.51) | SIGMAR1TBXAS1TBXA2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130296346-A1 | DIPHENYL-AMINE DERIVATIVES: USES, PROCESS OF SYNTHESIS AND PHARMACEUTICAL COMPOSITIONS | FAES FARMA, S.A. (ES) | 2013-11-07 | — | — | US | disclosed |
| EP-2465498-A1 | Diphenyl-amine derivatives: uses, process of synthesis and pharmaceutical compositions | FAES FARMA, S.A. (ES) | 2012-06-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130296346-A1 | DIPHENYL-AMINE DERIVATIVES: USES, PROCESS OF SYNTHESIS AND PHARMACEUTICAL COMPOSITIONS | CYP2D6, DDC, PAH | SIGMAR1 1329/4885TBXAS1 517/4885TBXA2R 478/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.